奥布替尼治疗B细胞淋巴瘤临床应用专家共识(2024年版)  

Expert consensus on orelabrutinib in treatment of B-cell lymphoma(2024 version)

作　　者：中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 赵东陆[2] Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Zhao Donglu(不详;Harbin Institute of Hematology&Oncology,Harbin 150010)

机构地区：[1]不详 [2]哈尔滨血液病肿瘤研究所,哈尔滨150010

出　　处：《白血病.淋巴瘤》2025年第1期1-7,共7页Journal of Leukemia & Lymphoma

摘　　要：布鲁顿酪氨酸激酶抑制剂(BTKi)是治疗B细胞恶性肿瘤的重要手段,改变了B细胞淋巴瘤患者的治疗模式与预后。奥布替尼是新型BTKi(Ⅰ类创新药),于2020年12月25日在中国获批上市。目前奥布替尼已被批准用于既往至少接受过1种治疗的成年人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、套细胞淋巴瘤、边缘区淋巴瘤。近年来,奥布替尼在其他B细胞淋巴瘤领域亦获得了良好的疗效和安全性。为满足当前临床需求,规范奥布替尼临床用药,专家组成员结合最新的研究进展,在2021年版奥布替尼治疗B细胞淋巴瘤中国专家推荐临床应用指导原则的基础上,讨论并制定了该共识。Bruton tyrosine kinase inhibitor(BTKi)is an important means of treating B-cell malignancies and have changed the treatment patterns and prognosis for patients with B-cell lymphoma.Orelabrutinib is a new BTKi(a ClassⅠinnovative drug)that was approved for marketing in China on December 25,2020.Currently,orelabrutinib has been approved for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma,mantle cell lymphoma and marginal zone lymphoma who have received at least one prior treatment.In recent years,orelabrutinib has also achieved good efficacy and safety in other B-cell lymphoma areas.In order to meet the current clinical needs and standardize the clinical use of orelabrutinib,the mumbers of the expert group discussed and formulated this consensus based on the guidance for the clinical practice of orelabrutinib in B-cell lymphoma recommended by Chinese experts in 2021,and combined with the latest research progress.

关 键 词：淋巴瘤 B细胞 布鲁顿酪氨酸激酶抑制剂 奥布替尼 治疗结果 

分 类 号：R73[医药卫生—肿瘤]